4 completed, 1 recruiting. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Hereditary Angioedema (HAE): new trials by email Literature Review of Hereditary Angioedema (HAE) trials Research Report on Hereditary Angioedema (HAE)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule - Hereditary Angioedema (HAE), Angioedema | Phase 1 / Phase 2 | Recruiting | Institute for Asthma and Allergy | 10 | 2025-03-10 | 2025-07-02 |
| Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects Recombinant human C1 esterase inhibitor, Placebo, SHP623 - Hereditary Angioedema (HAE) | Phase 1 | Completed | Shire | 48 | 2016-02-19 | 2021-06-03 |
| A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants DX-2930, Placebo - Hereditary Angioedema (HAE) | Phase 1 | Completed | Shire | 38 | 2014-05-14 | 2021-05-27 |
| Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers Icatibant (30 mg) - Hereditary Angioedema (HAE) | Phase 1 | Completed | Shire | 12 | 2014-02-21 | 2021-06-03 |
| A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects DX-2930, Placebo - Hereditary Angioedema (HAE) | Phase 1 | Completed | Shire | 32 | 2013-08-12 | 2021-05-17 |
Angioedemas, Hereditary (5) · Angioedema (2) · Cardiovascular Diseases (1) · Genetic Diseases, Inborn (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Skin Diseases (1) · Skin Diseases, Vascular (1) · Urticaria (1) · Vascular Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Hereditary Complement Deficiency Diseases (5) · Immunologic Deficiency Syndromes (5) · Primary Immunodeficiency Diseases (5) · Skin and Connective Tissue Diseases (5) · Cardiovascular Diseases (4) · Genetic Diseases, Inborn (4) · Hypersensitivity (4) · Hypersensitivity, Immediate (4) · Immune System Diseases (4) · Skin Diseases (4) · Skin Diseases, Vascular (4) · Urticaria (4) · Vascular Diseases (4) · Angioedema (3)
lanadelumab (2) · conestat alfa (1) · icatibant (1)
Shire (4) · Institute for Asthma and Allergy (1)
United States (5) · Italy (1) · Jordan (1)